Humulin M3 (30/70) Cartridge

Humulin M3 (30/70) Cartridge is a premixed insulin human product containing a 30% rapid‑acting soluble insulin and 70% intermediate‑acting isophane insulin, supplied in a cartridge for subcutaneous injection with an insulin pen. It is marketed in the European Union and belongs to the antidiabetic drug class (ATC code A10AD02). It is used to help control blood glucose levels in people with diabetes and is stored in a controlled environment until use.

Humulin M3 (30/70) is indicated for the management of blood glucose in adults with diabetes mellitus.

- Type 1 diabetes mellitus requiring basal and prandial insulin coverage. - Type 2 diabetes mellitus when oral agents and lifestyle measures are insufficient. - Situations where a premixed insulin simplifies dosing schedules. - Use in patients who prefer a single daily injection of a mixed formulation. - Adjunct to diet and exercise in insulin‑dependent diabetes. - Management of fluctuating glucose levels during periods of variable carbohydrate intake. - Combination therapy with other antidiabetic agents when tighter glycemic control is required.

Adverse reactions reported with Humulin M3 can be grouped into common and serious categories.

Common: - Hypoglycemia (low blood glucose) - Injection site pain or erythema - Lipodystrophy at the injection site - Weight gain - Edema (fluid retention) - Nausea - Headache - Dizziness

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as urticaria or anaphylaxis - Insulin antibody formation causing resistance - Lipohypertrophy with repeated injections - Acute pancreatitis (rare) - Severe allergic reaction (anaphylactic shock) - Persistent hypoglycemia - Hypersensitivity with skin rash

When using Humulin M3, several precautions should be considered to minimize risks and ensure safe therapy.

- Monitor blood glucose regularly, especially when initiating or adjusting dose. - Adjust dose during periods of illness, stress, or changes in diet and physical activity. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Avoid use in individuals with known hypersensitivity to human insulin or any excipients. - Educate patients on recognizing and treating hypoglycemia promptly. - Store the cartridge at controlled temperatures and discard after the indicated in‑use period.

Humulin M3 may interact with other medicines or substances that affect blood glucose levels or insulin action.

Avoid: - Concurrent use of other rapid‑acting insulins without dose adjustment. - High‑dose beta‑blockers that mask hypoglycemia symptoms. - Systemic corticosteroids that increase insulin resistance. - Use of insulin secretagogues such as meglitinides without adjusting Humulin M3 dose.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that can potentiate hypoglycemia. - ACE inhibitors or ARBs, which may enhance insulin sensitivity. - Alcohol consumption, especially on an empty stomach. - Thyroid hormone therapy, which can alter insulin requirements. - Concurrent use of MAO inhibitors, which may affect glucose metabolism.